

QC and Reference Material for Genetic Testing – US Regulatory Aspects

Zivana Tezak, Ph.D.

Office of *In Vitro* Diagnostic Device
Evaluation and Safety (OIVD)

Center for Devices and Radiological Health, FDA



Outline

- Brief Overview - FDA regulations for IVDs
- Control and reference material:
 - Regulatory Strategies / Requirements
 - Technical Issues
 - Current Initiatives
- Information Sources and Contacts

FDA Regulations

- Federal Food, Drug and Cosmetic Act as amended by:
 - o Medical Device Amendments 1976
 - o Safe Medical Devices Act (SMDA) -1990
 - o FDA Modernization Act (FDAMA) -1997
 - o Medical Device User Fee and Modernization Act (MDUFMA) - Oct 2002
- Office Of In Vitro Diagnostic Device Evaluation and Safety – Nov 2002

Medical devices: In vitro diagnostic (IVD) products

"reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. ... for use in the collection, preparation, and examination of specimens from the human body." [21 CFR 809.3]

Distribution (where used)

- clinical laboratories
- other settings: point-of-care (e.g., ER, out-patient clinics), over-the-counter, prescription home use

Risk-Based Device Classification

- Class I: common, low risk devices
 - ✓ General control requirements
 - ✓ Most exempt from premarket submission
- Class II: more complex, higher risk
 - ✓ Special controls and general controls
 - ✓ Premarket Notification [510(k)]
- Class III: most complex, highest risk
 - ✓ Supported by valid scientific evidence
 - ✓ No established predicate, or new types safety and effectiveness questions
 - ✓ Premarket Application [PMA]

Genetic / Genomic / Molecular Tests

FDA – ensure that:

- commercially distributed genetic tests are **reliable** (safe & effective)
- patients and health care professionals understand both the **value** and the **limitations** of such testing (education; appropriate use)

QC material – means of ensuring consistency and reliability of genetic testing

Regulatory oversight of Quality Control Material (US)

- Premarket (Class I, exempt, Class II)
- Compliance
- Clinical laboratory use
- QC requirements

Regulatory Requirements for Quality Control Material

- General Controls
 - Register (21 CFR 807.20) and List
 - Good Manufacturing Practices (GMP)
http://www.fda.gov/cdrh/dsma/gmp_man.html
 - Report device failures
 - Labeling (regulations 21 CFR 801 or 809)
 - Inventory of tests on the market
 - System for remedying device failures

Clinical laboratories – QC requirements

CMS [42 CFR §493.1256(d)(3)(iii)]48

- **positive** control material
- **negative** control material
- 2 different concentrations (if quantitative assay)
- control for **extraction**
- amplification (inhibition) control
- **external, internal** controls

Regulatory Strategies for Quality Control Material

- Regulated / Submitted:
 - with the assay
 - separately
- Reviewed the same in either case
- Class I or II (both have general control requirements)

QC material - review

- Unassayed controls
 - no value assigned
 - not linked to specific device/assay
- Assayed controls
 - assigned value
 - device link

(guidance: <http://www.fda.gov/cdrh/ode/99.html>)

Submission Content

- Intended use/indications for use
- Performance characteristics
 - Analytical
 - Clinical
- Labeling (package insert)

Intended Use

- assayed or unassayed
- for quantitative, semi-quantitative or qualitative testing
- matrix, analyte(s) to monitor
- analytical procedure, portion of the assay to monitor

**concentration should challenge the medical decision point of the assay;
alternatively, monitor for gross systematic errors.**

Reagent Information

- nucleic acid segment, sequence
- sources of components:
 - human, animal, synthetic, purified chemicals
 - recombinant, microorganism (ATCC strain)
- human donor characterization
- media, cell line used for culture
- matrix, stabilizers, preservatives, etc in control mixture
- volumes, concentrations, particle sizes
- inactivation methods

Performance Characteristics

Stability studies:

- real time (shelf life)
- ambient temperature (shelf life)
- stress testing (shipment)

Clinical laboratory evaluations – independent evaluation of consistency and performance of QC material by the intended user in the situations where most likely will be used

- validation (methods, i.e. sequencing mutations)
- reproducibility

Stress testing

Evaluate control reagent using corresponding assay after exposure to stress conditions:

- Elevated temperature studies (evaluate reactivity of several lots, unopened bottles)
- Freeze/thaw studies – multiple cycles – effect on reactivity
- Open vial stability – at various time intervals after bottles of reagent are opened

Labeling

- Procedures / instructions for use
 - handling, storage and stability for both opened and closed conditions
 - precautions (i.e., sodium azide warning)
- Performance characteristics
 - any matrix bias
 - ability or sensitivity to detect known analytical problems

Labeling (cont.)

- Performance characteristics / Expected values
 - range, SD, CV, CI
 - each constituent, level
 - protocols used to establish the acceptable value/range (e.g., low, mid or high level)
 - analytical methods, number of testing replications, test runs and instruments, statistical analyses
- Limitations

Current reference use

- Reference methods
- Reference materials/standards
 - Limited
 - Source – WHO, NIST, CDC, NIH, CBER etc.
 - Calibrators and controls – FDA regulated
 - Traceability
 - Assign values
 - Standardize and control assay performance

Synthetic nucleic acid based controls

- Unique sequences (can be customized)
- Can be highly useful for multiplex assays
- Internal control
- Can be e.g. controls for reverse transcription, labeling, hybridization, instrumentation
- Stable

Current Initiatives

➤ QC material for genetic testing (CDC)

- Huntington QC material
- Fragile X QC material

➤ Microarray controls

- ERCC (External RNA Controls Consortium)
- MAQC (Microarray Quality Control)

Sources of Information

- General information
 - <http://www.fda.gov/cdrh/index.html>
- OIVD website
 - <http://www.fda.gov/cdrh/oivd/>

OIVD Publications

Tezak Z, Ranamukhaarachi D, Russek-Cohen E, Gutman SI.
FDA Perspectives on Potential Microarray-based Clinical Diagnostics.
Human Genomics. In press.

Harper CC, Philip R, Robinowitz M and Gutman SI.
FDA Perspectives on Pharmacogenetics Testing.
Expert Rev Mol Diagn. 2005 Sep;5(5):643-8.

Mansfield E, O'Leary TJ and Gutman SI.
Food and Drug Administration Regulation of In Vitro Diagnostic Devices.
Journal of Molecular Diagnostics 7:1 p 2-7, Feb 2005.

Ardekani AM, Petricoin III EF and Hackett JL.
Molecular Diagnostics: an FDA perspective.
Expert Rev Mol Diagn. 2003 March; 3(2): 129-140.

OIVD Contacts for Molecular Diagnostic Submissions

Joseph Hackett, PhD
jlh@cdrh.fda.gov

Uwe Scherf, PhD
uxs@cdrh.fda.gov


Robert Becker, MD, PhD
rlb@cdrh.fda.gov

Zivana Tezak, PhD
zxt@cdrh.fda.gov

Maria Chan, PhD
mmc@cdrh.fda.gov

Follow Good Science

- Standardization
- Transparency of data
- Sharing of data



Pre-IDE Process for IVDs

- Not an IDE (misnomer)
- Protocol review and regulatory guidance
- No charge to the sponsor
- Non-binding on either party
- Recommended for novel devices/uses:
 - Familiarize FDA with new products
 - Learn about latest FDA thinking
- Understand and clarify questions up-front
- Decrease uncertainty

<http://www.fda.gov/cdrh/oivd/presentations/042203-Altaie.html>

De novo 510(k)

- Process for regulating new unclassified devices
- Six in past year with two under review
- Broad but not over-reaching view of risk
- Turnaround ranges from 9 days to four months for good submissions